References
1. Ahuja CS, Wilson JR, Nori S, et al. Traumatic spinal cord injury. Nat Rev Dis Primers. 2017;3: 17018. Published 2017 Apr 27. doi:10.1038/nrdp.2017.18
2. Jain NB, Ayers GD, Peterson EN, et al. Traumatic spinal cord injury in the United States, 1993-2012. JAMA. 2015;313(22):2236-2243. doi:10.1001/jama.2015.6250
3. Hubscher CH, Herrity AN, Williams CS, et al. Improvements in bladder, bowel and sexual outcomes following task-specific locomotor training in human spinal cord injury. PLoS One. 2018;13(1):e0190998. Published 2018 Jan 31. doi:10.1371/journal.pone.0190998
4. Quel de Oliveira C, Refshauge K, Middleton J, de Jong L, Davis GM. Effects of Activity-Based Therapy Interventions on Mobility, Independence, and Quality of Life for People with Spinal Cord Injuries: A Systematic Review and Meta-Analysis. J Neurotrauma. 2017;34(9):1726-1743. doi:10.1089/neu.2016.4558
5. Baldassin V, Shimizu HE, Fachin-Martins E. Computer assistive technology and associations with quality of life for individuals with spinal cord injury: a systematic review. Qual Life Res. 2018;27(3):597-607. doi:10.1007/s11136-018-1804-9
6. Elmelund M, Klarskov N, Bagi P, Oturai PS, Biering-Sørensen F. Renal deterioration after spinal cord injury is associated with length of detrusor contractions during cystometry-A study with a median of 41 years follow-up. Neurourol Urodyn. 2017;36(6):1607-1615. doi:10.1002/nau.23163
7. Hamid R, Averbeck MA, Chiang H, et al. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol. 2018;36(10):1517-1527. doi:10.1007/s00345-018-2301-z
8. Myers JB, Lenherr SM, Stoffel JT, et al. Patient Reported Bladder Related Symptoms and Quality of Life after Spinal Cord Injury with Different Bladder Management Strategies. J Urol. 2019;202(3):574-584. doi:10.1097/JU.0000000000000270
9. Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012;62(5):816-830. doi:10.1016/j.eururo.2012.02.036
10. Krhut J, Borovička V, Bílková K, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37(7):2226-2233. doi:10.1002/nau.23566
11. Blok B, Castro-Diaz D, Del Popolo G, et al., EAU Guidelines on Neuro-urology. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020. ISBN 978-94-92671-07-3.
12. Andersson KE. Potential Future Pharmacological Treatment of Bladder Dysfunction. Basic Clin Pharmacol Toxicol. 2016;119 Suppl 3:75-85. doi:10.1111/bcpt.12577
13. Andersson KE. Pharmacotherapy of the overactive bladder. Discov Med. 2009;8(42):118-124.
14. Carbone A, Palleschi G, Conte A, et al. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol. 2006;29(4):206-214. doi:10.1097/01.WNF.0000228174.08885.AB
15. Kim YT, Kwon DD, Kim J, Kim DK, Lee JY, Chancellor MB. Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int Braz J Urol. 2004;30(4):275-278. doi:10.1590/s1677-55382004000400002
16. Ansari MS, Bharti A, Kumar R, Ranjan P, Srivastava A, Kapoor R. Gabapentin: a novel drug as add-on therapy in cases of refractory overactive bladder in children. J Pediatr Urol. 2013;9(1):17-22. doi:10.1016/j.jpurol.2011.10.022
17. Dash V, Bawa M, Mahajan JK, Kanojia RP, Samujh R, Rao KL. Role of gabapentin and anticholinergics in management of neurogenic bladder after repair of spina bifida - a randomized controlled study. J Pediatr Surg. 2016;51(12):2025-2029. doi:10.1016/j.jpedsurg.2016.09.030
18. Chua ME, See MC 4th, Esmeňa EB, Balingit JC, Morales ML Jr. Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment. Low Urin Tract Symptoms. 2018;10(2):135-142. doi:10.1111/luts.12152
19. Ferro S, Cecconi L, Bonavita J, Pagliacci MC, Biggeri A, Franceschini M. Incidence of traumatic spinal cord injury in Italy during 2013-2014: a population-based study. Spinal Cord. 2017;55(12):1103-1107. doi:10.1038/sc.2017.88
20. Joseph C, Andersson N, Bjelak S, et al. Incidence, aetiology and injury characteristics of traumatic spinal cord injury in Stockholm, Sweden: A prospective, population-based update. J Rehabil Med. 2017;49(5):431-436. doi:10.2340/16501977-2224
21. Joseph C, Andersson N, Bjelak S, et al. Incidence, aetiology and injury characteristics of traumatic spinal cord injury in Stockholm, Sweden: A prospective, population-based update. J Rehabil Med. 2017;49(5):431-436. doi:10.2340/16501977-2224
22. Chen Y, He Y, DeVivo MJ. Changing Demographics and Injury Profile of New Traumatic Spinal Cord Injuries in the United States, 1972-2014. Arch Phys Med Rehabil. 2016;97(10):1610-1619. doi:10.1016/j.apmr.2016.03.017
23. Kim KT, Chang HK, Kim CH, et al. Basic neurourology. J Exerc Rehabil. 2019;15(6):747-750. Published 2019 Dec 31. doi:10.12965/jer.1938744.372
24. Chung YG, Seth A, Doyle C, et al. Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury. PLoS One. 2015;10(11):e0141492. Published 2015 Nov 3. doi:10.1371/journal.pone.0141492
25. Oliveira R, Coelho A, Franquinho F, Sousa MM, Cruz F, D Cruz C. Effects of early intravesical administration of resiniferatoxin to spinal cord-injured rats in neurogenic detrusor overactivity. Neurourol Urodyn. 2019;38(6):1540-1550. doi:10.1002/nau.24032
26. Wada N, Kadekawa K, Majima T, et al. Urodynamic effects of intravenous and intrathecal administration of E-series prostaglandin 1 receptor antagonist on detrusor overactivity in rats with spinal cord injury. Neurourol Urodyn. 2018;37(1):132-137. doi:10.1002/nau.23319
27. Miyazato M, Sasatomi K, Hiragata S, et al. GABA receptor activation in the lumbosacral spinal cord decreases detrusor overactivity in spinal cord injured rats. J Urol. 2008;179(3):1178-1183. doi:10.1016/j.juro.2007.10.030
28. Andrade EL, Forner S, Bento AF, et al. TRPA1 receptor modulation attenuates bladder overactivity induced by spinal cord injury. Am J Physiol Renal Physiol. 2011;300(5):F1223-F1234. doi:10.1152/ajprenal.00535.2010
29. Santos-Silva A, Charrua A, Cruz CD, Gharat L, Avelino A, Cruz F. Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist. Auton Neurosci. 2012;166(1-2):35-38. doi:10.1016/j.autneu.2011.09.005
30. Ogawa T, Sasatomi K, Hiragata S, et al. Therapeutic effects of endothelin-A receptor antagonist on bladder overactivity in rats with chronic spinal cord injury. Urology. 2008;71(2):341-345. doi:10.1016/j.urology.2007.10.025
31. Khera M, Boone TB, Salas N, Jett MF, Somogyi GT. The role of the prostacyclin receptor antagonist RO3244019 in treating neurogenic detrusor overactivity after spinal cord injury in rats. BJU Int. 2007;99(2):442-446. doi:10.1111/j.1464-410X.2007.06615.x
32. Sasatomi K, Hiragata S, Miyazato M, Chancellor MB, Morris SM Jr, Yoshimura N. Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury. Urology. 2008;72(3):696-700. doi:10.1016/j.urology.2007.12.002
33. Ozkürkçügil C, Kömür O, Ozkan L. Effect of memantine on overactive detrusor in rats with spinal cord injury. Kaohsiung J Med Sci. 2010;26(5):251-255. doi:10.1016/S1607-551X(10)70036-X
34. Krhut J, Borovička V, Bílková K, et al. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2018;37(7):2226-2233. doi:10.1002/nau.23566
35. Maniscalco GT, Aponte R, Bruzzese D, et al. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study. Neurol Sci. 2018;39(1):97-102. doi:10.1007/s10072-017-3148-6
36. Schröder A, Albrecht U, Schnitker J, Reitz A, Stein R. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial. Neurourol Urodyn. 2016;35(5):582-588. doi:10.1002/nau.22755
37. Watanabe M, Yamanishi T, Honda M, Sakakibara R, Uchiyama T, Yoshida K. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. Int J Urol. 2010;17(11):931-936. doi:10.1111/j.1442-2042.2010.02635.x
38. Schulte-Baukloh H, Mürtz G, Heine G, et al. Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study. J Pediatr Urol. 2012;8(4):386-392. doi:10.1016/j.jpurol.2011.07.014
39. Amarenco G, Sutory M, Zachoval R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36(2):414-421. doi:10.1002/nau.22945
40. Weckx F, Tutolo M, De Ridder D, Van der Aa F. The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol. 2016;5(1):63-71. doi:10.3978/j.issn.2223-4683.2016.01.10
41. Davari M, Amani B, Amani B, Khanijahani A, Akbarzadeh A, Shabestan R. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis. Korean J Pain. 2020;33(1):3-12. doi:10.3344/kjp.2020.33.1.3
42. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm. 2019;15(8):953-958. doi:10.1016/j.sapharm.2018.06.018
Table 1. Clinical data of the cohort 1.